PDL BioPharma, Inc.
PDLI
PDLI was delisted on the 30th of December, 2020.
8 hedge funds and large institutions have $37.9M invested in PDL BioPharma, Inc. in 2021 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, reducing their positions, and 5 closing their positions.
3% more capital invested
Capital invested by funds: $36.7M → $37.9M (+$1.12M)
27% less funds holding
Funds holding: 11 → 8 (-3)
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PPA
Parametric Portfolio Associates
Seattle,
Washington
|
-$351K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PWAM
1
Park West Asset Management
San Francisco,
California
| $37.7M | – | – | – |
|
2
Public Employees Retirement Association of Colorado
Denver,
Colorado
| $141K | – | – | – |
|
|
PPA
3
Parametric Portfolio Associates
Seattle,
Washington
| – | -$351K | -142,162 | Closed |
|
PDLI Hedge Fund Activity: Q2 2021 in Review
8 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in PDL BioPharma, Inc. (PDLI) for Q2 2021, worth a combined $37.9M — up 3.1% from $36.7M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of PDLI and 2 opened new positions — a net loss of 3 holders — while 0 trimmed existing stakes and 1 added.
The largest seller was Parametric Portfolio Associates, exiting entirely with an estimated $351K sold.
- 8 institutional investors held PDL BioPharma, Inc. (PDLI) as of Q2 2021, down from 11 in Q1 2021.
- Funds reported $37.9M of PDL BioPharma, Inc. stock for Q2 2021, up 3.1% quarter-over-quarter.
- 2 funds opened new PDL BioPharma, Inc. positions in Q2 2021 and 5 closed out, a net change of -3 holders.
- The largest PDL BioPharma, Inc. seller in Q2 2021 was Parametric Portfolio Associates, an estimated $351K sold.
Based on aggregated 13F filings for Q2 2021.